Table 2.
The association between metabolizer status, SLC6A4 and SLC6A2 allele variants, and SNRIs remission.
| Gene | Drug | Remission rate by genotype | P-valuea | Assuming linear effeetb ORc | P-valued | ||
|---|---|---|---|---|---|---|---|
| CYP2D6 | PMd | IM/EMd | URMd | ||||
| Duloxetine | 0(0%) | 6(24.0%) | 0(0%) | 0.462 | 1.559 | 0.762 | |
| Venlafaxine | 1(10.0%) | 22(34.9%) | 5(71.4%) | 0.027 | 4.727 | 0.018 | |
| CYP2C19 | PMd | IM/EMd | URMd | ||||
| Duloxetine | 1(50.0%) | 7(24.1%) | 0(0%) | 0.559 | 0.266 | 0.332 | |
| Venlafaxine | 0(0%) | 26(35.1%) | 2(33.3%) | 0.650 | 1.194 | 0.825 | |
| SLC6A4e 5-HTTLPR | L/Ld | S/Ld | s/sd | ||||
| Duloxetine | 1(16.7%) | 6(35.3%) | 0(0%) | 0.135 | 0.692 | 0.603 | |
| Venlafaxine | 8(29.6%) | 17(38.6%) | 3(27.3%) | 0.645 | 1.061 | 0.869 | |
| SLC6A4e 5-HTVNTRf | 12/12 | 9/12, 10/12, 9/10 | 10/10 | ||||
| Venlafaxine | 13(39.4%) | 9(30.0%) | 5(29.4%) | 0.671 | 0.777 | 0.423 | |
| SLC6A2e G1287A | AA | GA | GG | ||||
| Duloxetine | 0(0%) | 8(28.6%) | 5(20.8%) | 0.270 | 0.908 | 0.853 | |
| Venlafaxine | 4(40.0%) | 11(28.9%) | 13(39.4%) | 0.604 | 0.880 | 0.715 | |
| SLC6A2e T182C | C/C | T/C | T/T | ||||
| Duloxetine | 1(25.0%) | 9(37.5%) | 3(10.3%) | 0.059 | 2.525 | 0.07 | |
| Venlafaxine | 0(0%) | 17(43.6%) | 11(29.7%) | 0.05 | 1.009 | 0.981 | |
a
Chi-square test.
b
By coding different allele variants as continuous variable.
c
OR, Odds Ratio.
d
Linear regression model.
d
PM, poor metabolizer; IM/EM, intermediate metabolizer/extensive metabolizer; URM, ultra-rapid metabolizer;
d
L, long; S, short allele variants;
e
SLC6A4, serotonin transporter; SLC6A2, norepinephrine transporter.
f
VNTR, variable number of tandem repeats.